CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
中枢神经系统淋巴瘤的新型治疗策略：CAR-T 细胞治疗与伽玛刀放疗的整合
英文原题：A Novel Therapeutic Strategy for Central Nervous System Lymphoma: Integrating Chimeric Antigen Receptor T-Cell Therapy and Gamma Knife Radiation.
查看英文原题
A Novel Therapeutic Strategy for Central Nervous System Lymphoma: Integrating Chimeric Antigen Receptor T-Cell Therapy and Gamma Knife Radiation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
中枢神经系统淋巴瘤（CNSL）是一种侵袭性疾病，治疗选择有限且研究不足，难治性病例尤为如此。一线治疗通常包括以大剂量甲氨蝶呤（HD-MTX）诱导，随后采用自体干细胞移植或全脑放疗（WBRT）巩固。然而，WBRT可导致显著神经毒性，因此有人提出采用不同剂量和分割方案的局部放疗，例如伽玛刀立体定向放射外科（GK-SRS）。对于难治性疾病，嵌合抗原受体（CAR）T细胞疗法已开始进入临床应用，但关键注册试验排除了CNS受累患者。本文报告一例62岁患者，其继发性CNSL（SCNSL）难治，既往接受WBRT，随后接受CAR-T 细胞疗法联合GK-SRS并成功治疗。
展开英文摘要原文
Central nervous system lymphoma (CNSL) is an aggressive disease with limited well-studied options for treatment, especially refractory treatment. First-line treatment usually includes high-dose methotrexate (HD-MTX) for induction and either autologous stem cell transplantation or whole-brain radiation therapy (WBRT) as consolidation.
However, WBRT can result in significant neurotoxicity, so the use of focal radiation (i. e. , gamma knife-stereotactic radiosurgery (GK-SRS)) of varying doses and fractions has been proposed. In the case of refractory disease, chimeric antigen receptor (CAR) T-cell therapy has begun to be used clinically, but patients with CNS involvement were left out of key approval trials.
Here, we present a case of a 62-year-old patient with refractory secondary CNSL (SCNSL) previously treated with WBRT who was successfully treated with a combination of CAR T-cell therapy and GK-SRS.
论文信息
- 作者
- Hickmann K、DiLeo R、Faringer K、Peterson C、Wegner R、Horne Z、Samhouri Y
- 第一作者单位
- Drexel University College of Medicine, Philadelphia, PA, USA.United States
- 通讯作者单位
- Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.United States
- 文献类型
- 病例报告
- 期刊
- Journal of hematology2025 Apr
- 原文标识
- PubMed 40336923 · DOI 10.14740/jh2029
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →